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In Brief
Crystal structures of a 2A adrenergic receptor (a 2A AR) reveal the molecular basis for the diversity in adrenergic receptors. Qu et al. define compelling roles for key amino acids in ligand binding, partial agonism, and biased signaling of a 2A AR.
INTRODUCTION
There are nine human adrenergic receptors (a 1A , a 1B , a 1D , a 2A , a 2B , a 2C , b 1 , b 2 , and b 3 ) that mediate the central and peripheral actions of catecholamines (Hein and Kobilka, 1995; Philipp and Hein, 2004a) . Numerous compounds targeting adrenergic receptors, such as b-blockers, b 2 agonists, and a 2 agonists, have proven to be of therapeutic benefit in the treatment of a variety of diseases, including hypertension, angina pectoris, congestive heart failure, asthma, and depression (MacMillan et al., 1996; Philipp and Hein, 2004a; Ruffolo et al., 1993) . a 2A Adrenergic receptor (a 2A AR) agonists have been used for decades in clinic for the treatment of hypertension, attention-deficit/hyperactivity disorder, and anxiety because they have sympatholytic, sedating, and analgesic effects (Ruffolo et al., 1993; Tan et al., 2002) .
Although the selectivity of a 2 AR is being investigated in an accompanying paper (Chen et al., 2019) , we focus on understanding the structural basis of the binding and functional diversity of adrenergic receptors. More specifically, adrenergic receptors couple to different G proteins, with a 1 , a 2 , and b types mainly coupling to G q , G i/o , and G s , respectively (Lefkowitz et al., 1988) . Exceptionally, a 2A AR has a dual pharmacological effect in that it simultaneously couples to G i and G s to inhibit or stimulate adenylyl cyclase activity (Eason et al., 1992) . At low agonist concentrations, a 2A AR mainly couples to G i , whereas at high concentrations, G s coupling dominates. This unusual dual effect has not been well explained for any G-protein-coupled receptor (GPCR) .
Partial agonists of a 2A AR, such as clonidine and dexmedetomidine, tend to have better therapeutic benefits than full agonists (Philipp and Hein, 2004a; Tan et al., 2002; Vandergriff et al., 2000) . The mechanism of action of these partial agonists of a 2A AR remain incompletely understood. Previous research on partial agonism of b 1 AR and b 2 AR highlight the diversified roles of three serines (S 5.42 , S 5.43 , and S 5.46 ) in transmembrane helix (TM) 5, and an asparagine (N 6.55 ) in TM6 played in differentiating partial agonist from full agonist (superscripts refer to Ballesteros-Weinstein numbering; Ballesteros and Weinstein, 1995; Katritch et al., 2009; Masureel et al., 2018; Warne et al., 2011) . Specifically, in b 1 AR, full agonists form hydrogen bonds with S 5.42 and S 5.46 , but partial agonists form hydrogen bonds only with S 5.42 in a series of crystal structures. Whereas in b 2 AR, different hydrogen bond networks involving S 5.42 , S 5.43 , N 6.55 , and N 7.39 were formed upon full agonist and partial agonist binding, in crystal structures and in molecular dynamics simulations. In short, S 5.46 in b 1 AR and N 7.39 in b 2 AR play an essential role in differentiating partial agonist from partial agonist, respectively. The crystal structures of a 2A AR we solved, with partial agonist and antagonist bound, further provides the molecular basis for understanding partial agonism of GPCRs and facilitates the structure-based design of novel ligands with desired therapeutic efficacies.
RESULTS

Comparison of Two Adrenergic Receptor Structures
Two a 2A AR crystal structures were determined and co-crystallized with partial agonist (S)-4-fluoro-2-(1H-imidazol-5-yl)-1-isopropylindoline (RES) and antagonist (8aR,12aS,13aS)-12-(ethylsulfonyl)-3-methoxy- 8a,12a,13a-trimethyl-6,8,8a,9,10,11,12, 12a,13,13a-decahydro-5H-isoquinolino[2,1-g] [1,6]naphthyridine (RS 79948, or in short, RS) (Figures 1, S1, and S2; Table S1 ). The former structure is in an agonist-bound inactive state and the latter is in an inactive state.
To investigate conformational changes upon agonist binding across adrenergic receptors, we compared receptors a 2A AR, b 1 AR Warne et al., 2011) , and b 2 AR (Cherezov et al., 2007; Rasmussen et al., 2011; Rosenbaum et al., 2011) in the inactive, agonist-bound inactive, and active states. Remarkably, the overall structures of antagonist-bound and agonist-bound inactive states are very similar, with Ca root-mean-square deviations (RMSDs) of the a 2A AR (PDB: 6KUX/6KUY), b 1 AR (PDB: 2YCW/2Y02), and b 2 AR (PDB: 2RH1/3PDS) pairs at 1.1 Å , 0.5 Å , and 0.6 Å , respectively (Table  S2 ). The slightly greater value of a 2A AR is largely due to variations in the loop regions (Figures 1B and 1C) . In contrast, the overall structures of the adrenergic receptors must change significantly when forming complexes with the G protein (i.e., in fully active state), mainly due to the outward movement of the intracellular end of TM6 (Table S2) .
Although the overall structures of a 2A AR are similar to those of bARs, obvious differences are observed in the loop region and especially extracellular ends of TM4 for receptors in the same (inactive, agonist-bound inactive, or active) state ( Figure S3 ). Different from bARs, the extracellular end of TM4 in a 2A AR is unwound, which is consistent with the fact that the sequence of this region has two consecutive prolines that broke the helix. Connected to the unwound end of TM4, the starting part of ECL2 in a 2A AR has the typical intrinsically disordered sequence ''GGGGGPQP,'' and indeed the electron density of this part is missing in the structure. The unwound extracellular end of TM4 and the intrinsically disordered region of ECL2 together reflect the highly dynamic nature of ECL2 in a 2A AR. In contrast, in bARs, the starting part of ECL2 is helical and lacks glycine or proline. Importantly, ELC2 has an extra pair of cysteines that form an intra-ECL2 disulfide bond, which further stabilizes its overall conformation. Other ECLs also have notable differences between a 2A AR and bARs. The unique composition and conformation of each ECL in a 2A AR may affect the shape and dynamics of the pocket vestibule and, as we found in the case of a 2C AR (Chen et al., 2019) , may have an impact on ligand selectivity.
The Ligand-Binding Diversity of Adrenergic Receptors Electron densities for RES and RS 79948 in the two structures of a 2A AR enable us to convincingly make the placement of the two ligands ( Figure S1 ). The two ligands show strong interactions with residues in the pocket of a 2A AR, both including a salt bridge between the ligand's positively charged nitrogen atom and D113 3.32 -the conserved residue involved in ligand binding in all aminergic receptors and opioid receptors (Figures 2A-2D ). The binding pocket of a 2A AR is composed of 12 residues (Figure S4) . Although the backbone conformations of the pocketforming residues are rather similar in the two a 2A AR structures, the shapes of the two binding pockets are strikingly different due to the repacking of four sidechains (F412 7.39 , Y416 7.43 , Y394 6.55 , and D113 3.32 ) upon binding with different ligands (Figures 2C, 2E, . These dramatic sidechain rearrangements reflect the highly plastic nature of the receptor to accommodate ligands with very different chemical scaffolds, such as RES and RS 79948 (Figures 2A and 2B) .
Interestingly, when we tried to dock agonists and antagonists of a 2A AR into the two structures, we found that agonists (especially when containing an imidazole ring head like RES) fit better in the RES-bound structure (i.e., agonist-bound inactive state), whereas antagonists fit better in the RS-bound structure (i.e., inactive state) (Table S3 ). This finding implies that the shapes of the pockets of the two structures are specific to the agonists and antagonists of this receptor. Conversely, in bAR, generally agonists can be docked into the pocket of antagonist-bound structures, and vice versa, which reflects the relative rigidity of the binding pocket of bAR (Beuming and Sherman, 2012) . F412 7.39 Is Essential for a 2A AR Agonist Binding as a Switching Lid of an Aromatic Cage Among these conformational rearranged residues, the most intriguing is F412 7.39 , which functions as a switching lid for the pocket. Large ligands, like RS 79948 with a saturated ring system, push F412 7.39 aside, making the pocket large and open. Conversely, small ligands, like RES, can induce the closure of the lid (i.e., F412 7.39 ) to form an aromatic cage together with residues W387 6.48 , F390 6.51 , and Y416 7.43 ( Figure S4E ). By forming the aromatic cage around the cation in the ligand not only is the steric of the site tightly defined but also the energetics. Notably, the residue at 7.39 is one of the three non-conserved residues (the other two are 6.55 and 5.43) ( Figure S5 ) in the binding pocket of adrenergic receptors (Figures 2C and 2D; Table  S4 ). Thus, the ''switching lid'' phenomenon seems unique to aARs. In fact, even among aminergic and opioid receptors, only aARs, muscarinic receptors, and two histamine receptors (H3 and H4) have aromatic residues at the four positions 6.48, 6.51, 7.39, and 7.43 (Table S4 ). Unlike a 2A AR, in muscarinic receptors, there is no dramatic repacking of Y 7.39 upon agonist binding; thus, Y 7.39 forms a rather static cage restricting the muscarinic ligands while isolating the allosteric modulator from the ligand-binding pocket ( Figures S4E and S4F ). Such a rigid or flexible aromatic cage plays a substantial role in cation recognition in these receptors. Thus, it has particular implications for ligand discovery. This aromatic cage was not observed in bARs (Figures 2F and 2G) where the residue at 7.39 is a much smaller asparagine and shows no obvious conformational changes during various ligand binding because N 7.39 is involved in a stable hydrogen bond with the conserved positively charged ligand nitrogen ( Figure 2D ). Interestingly, the F412 7.39 N mutation in a 2A AR (i.e., mutation to the residue at 7.39 in bARs) abolished the function of all four partial and full agonists we tested (clonidine, guanabenz, UK14,304, and epinephrine), reflecting the essential p-p and cation-p interactions provided by F412 7.39 for the activity of a 2A AR agonists ( Figure S6A) . Similarly, the F312 7.39 A/L mutation in a 1A AR also abolishes the binding of ligands containing an imidazoline ring (Waugh et al., 2001) , which is indicative of the critical function of the phenylalanine at 7.39 for aARs. Interestingly, the F412 7.39 N mutation in a 2A AR has no response to two b 2 AR selective agonists, namely salmenterol and salbutamol ( Figure S6A ), implying the other two non-conserved residues (Y394 6.55 and C201 5.43 ) in the binding pocket also play important roles in ligand activity. Nevertheless, F412 7.39 N and Y394 6.55 N/F412 7.39 N abolish the activation activity of a 2A AR agonists and partial agonists, possibly due to the key role F412 7.39 plays in agonist binding; yet, they are still unable to trigger the activity of b 2 AR ligands x (Figures S6) . This finding implies that other regions, such as ECLs, may also be important for the binding and function of b 2 AR ligands.
Full but Not Partial Agonists Form Hydrogen Bonds with Y394 6.55 and S200 5.42 /S204 5.46 In both a 2A AR structures, Y394 6.55 , another non-conserved position in the ligand-binding pocket of adrenergic receptors, has no direct interaction with ligands, whereas in b 2 AR, N 6.55 forms a strong and conserved hydrogen bond with full agonist but not partial agonist ( Figure 2D) (Masureel et al., 2018) . In fact, hydrogen bond formation between N 6.55 and S 5.43 is believed to be a hallmark of the activation of bARs (Masureel et al., 2018) . As a result, the role of Y394 6.55 in a 2A AR is particularly intriguing. From the RES-bound structure, we knew that the partial agonist RES has no interaction with Y394 6.55 . We further checked the docking poses of representative full agonists (epinephrine, norepinephrine, and UK14,304) and partial agonists (clonidine, guanfacine, guanabenz, and dexmedetomidine) to see if Y394 6.55 contributes to partial agonism in a 2A AR as N 6.55 does in b 2 AR. The docking results show that all three full agonists of a 2A AR formed hydrogen bonds with Y394 6.55 and S200 5.42 /S204 5.46 , but all partial agonists do not ( Figure S7 ). The reason is that the tails of partial agonists generally are more hydrophobic, whereas tails of full agonists are more hydrophilic and, thus, are prone to hydrogen bond forming ( Figures S7 and S8 ). Because the movements of the extracellular end (which participates in ligand binding) and the intracellular end of TM6 (which interacts with the G protein) are more or less coupled, the strong interaction between full agonists and the extracellular end of TM6 could, in turn, push TM6 to be more kinked, which leads to more outward movement of the intracellular end of TM6 (i.e., more activated). In contrast, partial agonists can only form weaker interactions with TM6, which will lead to less outward movement of intracellular end of TM6 (i.e., less activated).
Notably, the roles of residues at positions 6.55, 5.42, and 5.46 in differentiating full agonist from partial agonist are diverse in adrenergic receptors. In a 2A AR and b 2 AR, full agonists form a hydrogen bond with 6.55 but partial agonists do not, although position 6.55 is not conversed in the two receptors (Table S5 ). In b 1 AR, full agonists form a hydrogen bond with S 5.46 but partial agonists do not , while in a 2A AR, full agonists cannot reach S 5.46 (Table S5) .
Role of Non-conversed Residues in Dual Coupling of a 2A AR to Two G Proteins
The movement of the intracellular end of TM6 is the hallmark of GPCR activation. Recent electron microscopy (EM) structures of GPCR-G i complexes revealed that TM6 are less kinked compared to those in GPCR-G s complexes (Draper-Joyce et al., 2018; García-Nafría et al., 2018; Kang et al., 2018; Koehl et al., 2018) . Thus, we hypothesized that TM6 of a 2A AR is in two different states when the receptor couples to different G proteins. Using functional studies of a 2A AR mutants, we investi-gated the role of the two non-conserved residues Y394 6.55 and C201 5.43 in dual coupling of a 2A AR to G i and G s by mutating them to residues in b 2 AR.
Consistent with previous reports, wild-type (WT) a 2A AR simultaneously coupled to both G i and G s proteins (termed ''dual effect''; Eason et al., 1992) when stimulated by full agonist adrenaline, UK14,304, or partial agonists clonidine and guanabenz ( Figure 3A ). Conversely, full or partial agonists of b 2 AR could only activate the G s signal ( Figure 3B ). We hypothesized that the non-conserved residues in the pocket may cause this dual effect. Therefore, we designed mutations to minimize the dual effect of a 2A AR. Surprisingly, with the single mutation Y394 6.55 N, the dual effect disappeared ( Figures  3C and 3D ), and the same result was achieved when adding another mutation: C201 5.43 S ( Figure 3E ). Both mutations caused an approximately 10-fold half maximal effective concentration (EC 50 ) loss ( Figure 3F ). These results confirm the key role Y394 6.55 plays in G-protein selectivity of a 2A AR.
G Protein Binding Site Diversity in Adrenergic Receptors
The activation of G protein is affected not only by the ligandbinding pocket but also by the G protein binding site. One region that may impact the G protein binding preference is ICL2, which often has more contacts with G s than G i ( Figure 4A ). Based on structural analysis of the b 2 AR-G s complex (PDB: 3SN6 21 ), we predicted that I 34.51 would form intensive hydrophobic interactions with H41 and F376 in G s ( Figure 4B) . Similarly, residue K144 34.56 would form electrostatic interactions with D139 in G s . As a result, two mutations, namely, I139 34.51 A and K144 34.56 A, were designed to see if they would hamper the coupling of G s when the receptor binds with full or partial agonists. To evaluate the G s signaling without the interference of G i signaling, pertussis toxin (PTX), which can selectively block the G i signaling pathway, was introduced. With PTX, we can see that WT a 2A AR has strong G s signaling for full agonists and rather weak G s signaling for partial agonists ( Figure 4C ). The I139 34.51 A mutant can abolish G s signaling for both partial agonists and full agonists ( Figure 4D ). Unlike I139 34.51 A, K144 34.56 A could selectively diminish the G s potency of partial agonists clonidine and guanabenz, leaving the G s potency of full agonists UK14,304 and epinephrine less affected ( Figure 4E) . Notably, the G i potencies of I139 34.51 A and K144 34.56 A mutants were more or less similar to that of WT a 2A AR for both partial and full agonists (Figures 4D, 4E, and 3F) .
The distinct pharmacological consequence of the two mutants (I139 34.51 A and K144 34.56 A) for partial and full agonists sheds light on the interplay between partial agonism and biased signaling of a 2A AR. Both mutants completely abolished the weak G s signaling for partial agonists, and they convert partial agonists clonidine and guanabenz to G i -biased agonists from the perspective of pharmacology. Unlike full agonists, partial agonists of a 2A AR lack of hydrophilic tails ( Figure S8 ) that can form hydrogen bonds with polar residues (Y 6.55 , S 5.42 or S 5.46 ) in the extracellular end of TM5 and TM6 ( Figure S7) ; thus, it is difficult for them to promote the outward movement of the intracellular end of TM6 as large as that required for G s coupling. The two mutations on ICL2 push the energy barrier for G s coupling induced by partial agonists even higher, and they become the last straw. On the other hand, full agonists can form strong inter-actions with the extracellular end of TM5 and TM6 ( Figure S7) ; thus, they may push the receptor to have a higher population in the G s -coupling state. The G s signaling pathway of a 2A AR induced by full agonists was largely unaffected by K144 34.56 A but was nearly abolished by I139 34.51 A. The difference highlights the curial role of I139 34.51 on G s coupling, and it infers that the I139 34.51 A mutant may lose the G s coupling ability. Taken together, these results demonstrate the essential role of ICL2 in G s coupling for partial agonists and reflects the allosteric communication between extracellular ligand binding and intracellular G protein coupling.
DISCUSSION
Our comparative study of two a 2A AR crystal structures in binding poses with very different ligands has identified key nonconserved residues from the ligand binding pocket (F412 7.39 and Y394 6.55 ) to the G protein coupling region (I139 34.51 , K144 34.56 ) that control adrenergic diversity through ligand TM6 has more buried surface in G i -coupled complexes, whereas ICL2 usually has less contacts with G i than G s . (B) AR-G s interface around ICL2, with the structure of a 2A AR aligned to that of G s -bound b 2 AR. I 34.51 and K 34.56 in a 2A AR are two residues that may interact with G s . (C-E) a 2A AR G s signaling when treated by PTX. (C) WT a 2A AR has strong G s signaling for full agonists and weak G s signaling for partial agonists. (D) I139 34.51 A mutation does not affect G i signaling of a 2A AR, but it completely abolishes G s signaling for both agonists and partial agonists. (E) K144 34.56 A mutant abolishes G s signaling for partial agonists but does not affect the G s coupling of full agonist too much. Data are represented as mean ± SEM of n R 3 independent experiments. See also Figures S7 and S8. binding, partial agonism, and G protein preference. Remarkably, we found that G protein signaling can be dramatically altered or even abolished by several single mutations, revealing how evolution has been able to achieve the diversity of adrenergic receptor function with minimal modifications. Together with accompanying insights on adrenergic selectivity (Chen et al., 2019) , our results will lay the foundation for next-generation drug discovery efforts targeting adrenergic receptors.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
METHOD DETAILS
Protein Engineering for Structure Determination The sequence of the human a 2A AR gene was synthesized by GenScript. The modified thermostabilized apocytochrome b 562 RIL (BRIL) was inserted into the receptor's third intracellular loop (IL3) at Thr227 and Arg365 of the human a 2A AR gene as a fusion partner, by overlapping PCR. The construct was further optimized by truncation of N-terminal residues 1-19 and C-terminal residues 446-450.
The DN-a 2A AR-RS-BRIL-DC DNA sequence was subcloned into a modified mammalian expression pTT5 vector, which contained a haemagglutinin (HA) signal sequence, a FLAG tag and 10 3 His tag, followed by a tobacco etch virus (TEV) protease cleavage site, before the N terminus of the truncated a 2A AR-RS gene. The DN-a 2A AR-RES-BRIL-DC DNA sequence was subcloned into a modified pFastBac1 vector for expression in Spodoptera frugiperda (Sf9) cells. The chimera sequence has a haemagglutinin (HA) signal sequence followed by a FLAG tag at the N terminus, a PreScission protease site and a 10 3 His tag at the C terminus. Two rationally designed mutations, I121 3.40 A and V122 3.41 W, and three mutations, I121 3.40 A, V122 3.41 W, and I155 4.47 L, were further introduced into the a 2A AR-RES and a 2A AR-RS genes, respectively, by standard QuickChange PCR.
Protein Expression a 2A AR-RS construct was transfected and expressed in HEK293F cells (Invitrogen) (Passage number is 12-20) using the FreeStyle TM293 Expression system (Invitrogen). HEK293F cells (Invitrogen) were cultured in suspension starting from densities of 0.2-0.3 3 10 6 cells/ml in a humidified incubator with 5% CO 2 at 37 C with a shaking speed of 130 rpm. Passage cells when cell density reached 1.6-1.8 3 10 6 cells/ml. Briefly, HEK293F cells were seeded on day 0 at 6 3 10 5 cells/ml in freeStyle 293 expression medium (Invitrogen). On day 2 the transduction was performed at a cell density of 1.0 to 1.2 3 10 6 cells/ml and cell viability over 95% using PEI-DNA complexes. Approximately 48 h post-transfection, cells were harvested by centrifugation at 400 g for 20 min at 4 C. Cells were stored at À80 C for future use. The a 2A AR-RES construct was transfected and expressed in Sf9 cells. The Bac-to-Bac Baculovirus Expression System (Invitrogen) was used to generate high-titer recombinant baculovirus (> 109 viral particles per ml). Recombinant baculovirus was produced by transfecting recombinant bacmids (2.5-5 mg) into Sf9 cells (2.5 mL, density of 106 cells/ml) using 5 mL of X-tremeGENE HP DNA Transfection Reagent (Roche) and Transfection Medium (Expression Systems). After 4 d of shaking at 27 C, P0 viral stock ($10 9 virus particles/ ml) was harvested as the supernatant of the cell suspension to produce high-titer viral stock. Viral titers were analyzed by flow cytometry on cells stained with gp64-PE antibody (Expression Systems). a 2A AR-RES was expressed by infecting Sf9 cells at a cell density of 2-3 3 10 6 cells/ml with P1 virus at MOI (multiplicity of infection) of 5. Cells were harvested by centrifugation for 48 h post infection and stored at À80 C for future use.
Protein Purification
Frozen cell pellets were thawed and lysed by repeated washing and centrifugation in the hypotonic buffer of 10 mM HEPES (pH 7.5), 10 mM MgCl2, 20 mM KCl, and the high osmotic buffer of 10mM HEPES (pH 7.5), 1.0 M NaCl, 10mM MgCl2, and 20 mM KCl, with EDTA free complete protease inhibitor cocktail tablets (Roche). The washed membranes were suspended in hypotonic buffer with 30% glycerol and flash-frozen with liquid nitrogen and stored at À80 C until further use. Purified membranes were thawed at room temperature and incubated with 50 mM RES or RS 79948 and inhibitor cocktail at 4 C for 3 h. The membranes were further incubated with 1.0 mg/ml iodoacetamide (Sigma) for 1 h. The membranes were solubilized in the buffer containing 50 mM HEPES (pH 7.5), 200 mM NaCl, 1% (w/v) n-dodecyl-beta-D-maltopyranoside (DDM, Anatrace), and 0.2% (w/v) cholesterol hemisucinate (CHS, Sigma-Aldrich) at 4 C for 2.5-3 h. The supernatants containing the solubilized a 2A AR proteins were isolated by high-speed centrifugation, and then incubated with TALON IMAC resin (Clontech) and 20 mM imidazole, at 4 C overnight. The resin was washed with 15 column volumes of washing buffer I containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 30 mM imidazole, and 50 mM RES or RS, and then 5 column volumes of washing buffer II containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 50 mM imidazole, and 50 mM RES or RS 79948. The protein was eluted using 2.5 column volumes of elution buffer containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.01% (w/v) DDM, 0.002% (w/v) CHS, 250 mM imidazole, and 50 mM RES or RS 79948. A PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was treated overnight with TEV protease to cleave the N-terminal FLAG/His tags from the proteins.
Lipidic Cubic Phase Crystallization
The purified a 2A AR protein in complex with RES or RS 79948 was screened for crystallization in lipidic cubic phase (LCP) with mixed molten lipid (90% (w/v) monoolein and 10% (w/v) cholesterol) at a protein/lipid ratio of 2:3 (v/v) using a mechanical syringe mixer (crystallizing membrane proteins using lipidic mesophases). LCP crystallization trials were set up using an NT8-LCP crystallization robot (Formulatrix). 96-well glass sandwich plates were incubated at 20 C in an automatic incubator/imager (RockImager 1000, Formulatrix) and imaged. Crystals were obtained in condition of 0.1M HEPES sodium pH 7.4, 310mM Ammonium tartrate dibasic, 36.5% PEG400 (RES) and condition of 0.1M Sodium citrate tribasic dihydrate pH 5.0, 290mM Ammonium chloride, 30% PEG400, 7% glycerol (RS 79948) and grew to full size in around two weeks. The crystals were harvested using micromounts (MiTeGen) and flashfrozen in liquid nitrogen.
